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Abstract
Background: Copy number variations (CNVs) can contribute to variable degrees of fitness and/or disease
predisposition. Recent studies show that at least 1% of any given genome is copy number variable when compared
to the human reference sequence assembly. Homozygous deletions (or CNV nulls) that are found in the normal
population are of particular interest because they may serve to define non-essential genes in human biology.
Results: In a genomic screen investigating CNV in Autism Spectrum Disorders (ASDs) we detected a heterozygous
deletion on chromosome 10p12.1, spanning the Patched-domain containing 3 (PTCHD3) gene, at a frequency of
~1.4% (6/427). This finding seemed interesting, given recent discoveries on the role of another Patched-domain
containing gene (PTCHD1) in ASD. Screening of another 177 ASD probands yielded two additional heterozygous
deletions bringing the frequency to 1.3% (8/604). The deletion was found at a frequency of ~0.73% (27/3,695) in
combined control population from North America and Northern Europe predominately of European ancestry.
Screening of the human genome diversity panel (HGDP-CEPH) covering worldwide populations yielded deletions
in 7/1,043 unrelated individuals and those detected were confined to individuals of European/Mediterranean/
Middle Eastern ancestry. Breakpoint mapping yielded an identical 102,624 bp deletion in all cases and controls
tested, suggesting a common ancestral event. Interestingly, this CNV occurs at a break of synteny between humans
and mouse. Considering all data, however, no significant association of these rare PTCHD3 deletions with ASD was
observed. Notwithstanding, our RNA expression studies detected PTCHD3 in several tissues, and a novel shorter
isoform for PTCHD3 was characterized. Expression in transfected COS-7 cells showed PTCHD3 isoforms colocalize
with calnexin in the endoplasmic reticulum. The presence of a patched (Ptc) domain suggested a role for PTCHD3
in various biological processes mediated through the Hedgehog (Hh) signaling pathway. However, further
investigation yielded one individual harboring a homozygous deletion (PTCHD3 null) without ASD or any other
overt abnormal phenotype. Exon sequencing of PTCHD3 in other individuals with deletions revealed compound
point mutations also resulting in a null state.
Conclusion: Our data suggests that PTCHD3 may be a non-essential gene in some humans and characterization of
this novel CNV at 10p12.1 will facilitate population and disease studies.
Background
Unbalanced submicroscopic genetic variation, known as
copy number variation (or CNV), is now well studied
[1-4]. CNV can potentially contribute to variable degrees
of fitness and/or disease predisposition [5-7]. In a recent
high-resolution microarray study of CNV in humans, it
w a sd e t e r m i n e dt h a ta tl e a s t0 . 7 8 %o ft h eg e n o m ei s
CNV between any two individuals [4]. Analyses of the
sequence assembly of a diploid genome at higher resolu-
tion determined that approximately 1.28% was CNV
[8,9]. While CNVs, and in particular CNV deletions, are
more often observed in gene poor regions [3,4], in the
highest resolution population study to date, 3,811 of the
validated biallelic deletions detected across 41 healthy
individuals were found to overlap 1,432 genes [4].
Homozygous CNV deletions, herein called CNV nulls,
affecting genes have previously been reported in the
human genome [10]. Though loss of gene functions
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loss of functions can be beneficial [11,12]. For example,
it is reported that homozygous mutations affecting
DARC or CCR5 result in resistance to certain categories
of malaria [13] or AIDS [14,15], respectively, without
posing any overt deleteriouse f f e c to nt h ei n d i v i d u a l s
carrying these mutations.
Here, we discover and characterize a CNV null
region in the human genome encompassing the
PTCHD3 gene that does not appear to be associated
with an overt phenotype. Breakpoint mapping indi-
cated a recurrent 102,624 bp deletion, suggesting a sin-
gle ancestral event that is now present in ~0.6-1.6% of
individuals of European ancestry. Expression analyses
showed PTCHD3 in several tissues with the highest
levels detected in lymph node, testes and tongue.
A previously uncharacterized shorter isoform was also
found and PTCHD3 isoforms were determined to co-
localize with calnexin in the endoplasmic reticulum in
transfected cells.
Methods
Sample Sets
The Ethics Board of Hospital for Sick Children approved
this study and all individuals providing samples signed
informed consents covering aspects of the experiments
conducted. Population control samples originated from
other studies and they were consented and collected
precisely for the aforesaid purpose (manuscripts citing
the source of the population control samples are men-
tioned below).
Initial screening of PTCHD3 deletions used an index
sample set of 427 probands diagnosed with ASD, all of
which met the criteria by the Autism Diagnostic Inter-
view-Revised (ADI-R) and Autism Diagnostic Observa-
tion Schedule (ADOS) [16]. We also screened another
177 cases from the same ASD population for the dele-
tion using qPCR. Additional control cohort microarray
data include 1,152 individuals from Ontario of predomi-
nately (95%) European ancestry genotyped on Affyme-
trix 500 K arrays [17], 1,123 Northern Europeans from
t h eG e r m a nP o p G e np r o j e c t[ 1 8 ]g e n o t y p e do nt h e
Affymetrix 6.0 SNP array, and 1,234 individuals of
European decent from the Ottawa River Valley [19] gen-
otyped on the Affymetrix 6.0 SNP array. DNA panels
used for quantitative PCR screening include 1,043 indi-
viduals from the HGDP-CEPH Human Genome Diver-
sity Panel [20], and a panel of 186 North American
Caucasians (Coriell Institute, USA). Ancestry of deletion
carriers was either self reported or in the cases where
microarray results were available, through inference
using the SNP genotypes clustered with the HapMap
samples as described previously [16].
Affymetrix GeneChip Human Mapping 500 K SNP and 6.0
Microarrays and CNV analysis
Affymetrix 500 K experiments and CNV analysis for the
ASD cases and Ontario controls were carried out as
described previously [16]. CNV analysis of Affymetrix
6.0 arrays is described elsewhere [21].
PTCHD3 Deletion Validation and Population Screening
For all cases where DNA was available, putative
PTCHD3 deletions were validated with SYBR-Green
I-based real time quantitative PCR (qPCR) using the
CFTR locus as a reference as described previously [16].
The same assay was used to screen the 177 additional
ASD probands, the 186 from the North American Cau-
casian Panel, and the 1,043 individuals from the HGDP-
CEPH for PTCHD3 deletions.
Deletion Breakpoint Analysis and Exon Sequencing
Putative PTCHD3 deletions in ASD and HGDP-CEPH
individuals were amplified with Stratagene Taq2000 poly-
merase and sequenced for breakpoint analysis. PCRs pro-
duct sizes of either 3 kb (primers PCR01F and PCR01R) or
2 kb (primers PCR01F and SEQ03R) were used for sequen-
cing using one or more of the primers SEQ01F, SEQ01R,
SEQ02R, SEQ03R, and SEQ04R (see Additional file 1 for
primer sequences). Sanger dideoxy-DNA sequencing and
Exon-sequencing of the PTCHD3 (NM_001034842) in
deletion carrier families was carried out using 12 different
amplicons. Primer sequences and PCR conditions used for
amplification are available on request.
Antibodies
Mouse monoclonal anti-Myc (sc-40); rabbit polyclonal
anti-calnexin (sc-11397) and goat anti-mouse HRP-
conjugated secondary antibody (sc-2005) were purchased
from Santa Cruz biotechnology (USA). Alexa Fluor 488
goat antimouse IgG1 (A-21121) and Alexafluor 555 goat
anti-rabbit IgG (A-21429) secondary antibodies were
purchased from Invitrogen.
PTCHD3 Cloning and Transfection
Using the primer set C (Additional file 2) the full-length
isoform of PTCHD3 was amplified from a pCR-Bunt
II-TOPO plasmid containing the full length human
PTCHD3. Primer set C was designed so that the ampli-
cons would have BamH1 and Xba1 restriction sites at
their 5’ and 3’ ends, respectively. For the shorter isoform
of PTCHD3, cDNA from human lymph node was initi-
ally amplified using the primer set D designed based on
sequences at/or around 5’UTR and 3’UTR regions of
PTCHD3, and the ~2,000 bp product of this amplifica-
tion was then used as a PCR template for primer set C.
The ~1,600 bp amplified product of the latter then was
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amplified long and short isoforms were then cloned into
TOPO A vectors (Invitrogen) for further amplification
in Top 10 competent cells (Invitrogen) following the
instruction provided by the manufacturer. Finally,
the long and short isoforms were both cloned into the
BamH I-Xba I site of a pcDNA3 vector (Invitrogen)
which had already been cloned with a c-Myc expressing
motif at its Kpn I-BamH I sites. COS-7 cells were
grown in DMEM medium containing 10% FBS. For wes-
tern blot assay, the cells were transfected with the plas-
mids expressing PTCHD3 using Genejuice transfection
reagent (Novagen) according to the instructions pro-
vided by the manufacturer. 48 hours later the cells were
lysed in western blot lysis buffer and transferred to
-20°C until used for further analysis. For immunocyto-
chemistry, COS-7 cells were grown in chamber slides
(Lab-Tek, Miles Laboratories) and transfected with the
plasmids using Genejuice as explained above. 48 hrs later
cells were used for immunolabelling as described below.
Western Blotting
Cell lysates were loaded on a 12% Polyacryamide gel and
the resolved proteins were transferred to a nitrocellulose
membrane following the general protocol for western
blotting. The membranes were blocked in 5% milk for
1 hour and then were incubated with the 1:1,000 dilu-
tion of anti-Myc primary antibody in blocking buffer
(5% milk) for another hour. After three washes of
10 minutes each, the membrane was incubated with
1:4,000 dilution of anti-mouse HRP-conjugated secondary
antibody for 45 minutes. Membranes were washed three
times, 10 minutes each and were developed using western
blotting chemiluminescence reagents (PerkinElmer).
Immunocytochemistry
Cells were briefly washed with PBS and fixed in 4% for-
maldehyde at room temperature for 20 minutes. The
fixed cells were permeablized in 0.1% triton (Sigma) in
PBS at room temperature for 10 minutes, washed twice
with PBS and were blocked in 10% Bovine Serum Albu-
min (BSA) (Sigma) in PBS at room temperature for
1 hour. The cells were then incubated in 1:100 dilution
of anti-Myc and anti-calnexin primary antibodies in 3%
BSA at room temperature for 1 hour. After 3 washes of
3 minutes each in PBS, the cells were incubated with
1 μg/ml of each of Alexa Fluor 488 goat antimouse
IgG1 and Alexafluor 555 goat anti-rabbit IgG in 3%
BSA for 45 minutes. After three washes in PBS, cells
were studied using confocal microscopy.
Multiple Tissue Northern (MTN) Blot
The probe was amplified using primer set shown in
Additional file 2, and the cDNA prepared from human
lymph nodes. Probe labelling was conducted using
32P-labelled dCTP (PerkinElmer) following the protocol
explained below. 1.2 μlo f0 . 1U / μl random hexamers
mix (GE Healthcare) was added to 7.2 μl of DNA probe
(11 ng/μl), boiled in a water bath for 2 minutes and
placed immediately on ice. 10 μl of 2.5× random prim-
ing buffer (0.5 M HEPES pH 6.6, 12.5 mM MgCl2,
28.8 mM b-mercaptoethanol, 125 mMTris pH 8.0 and
0.05 mM dATP/dGTP/dTTP mix) and 1 μlo f1 0 ×B S A
(New England Biolabs Inc.) were added to the probe
reaction and incubated at 22°C for 10 minutes followed
by addition of 4 U of DNA Poly I Klenow fragment
(USB corp.) and 5 μl (1.85 MBq) of [a
32P]dCTP. The
reaction was incubated at 22°C for 4 hours. 25 μlo fT E
with 0.1% SDS was added to the labelled probe and the
unincorporated nucleotides were removed by centrifuga-
tion at 700 g for 2 minutes on a ProbeQuant G-50
Sephadex micro column (GE Healthcare). The flow
through (labelled probe) was collected and the specific
activity was measured using a QC-2000 reader (BioS-
can). The labelled probe was then boiled for 10 minutes
and added to 5 ml of warm (68°C) buffer (clontech).
The probe mixture was then added to a Multiple Tissue
Northen blot membrane (Clonetch) that had been pre-
hybridized in ExpressHyb buffer for 1 hour at 68°C. The
hybridization proceeded at 68°C for 16 hours. The
membrane was washed and exposed overnight against
Biomax XAR autoradiograph film (Kodak) at -80°C and
developed.
Results and Discussion
Discovery and Population Distribution of PTCHD3
Deletion
Using Affymetrix 500K arrays to investigate structural
variation in individuals with Autism Spectrum Disorder
(ASD), we detected a recurrent heterozygous deletion at
chromosome 10p12.1. From our initial assessment the
deletion was found at a frequency of ~1.4% (6/427) and
was observed to intersect a single annotated gene,
Patched-domain containing 3 (PTCHD3). In all ASD
cases the deletion was found to be inherited, but none-
theless was determined to be an interesting candidate
gene since it had not previously been described in con-
trol populations. Additionally, we and others recently
described deletions in the X-linked PTCHD1,aPTCHD3
homologue, to be associated with ASD and intellectual
disability [16,21-23]. We then tested an additional 177
ASD probands and found two more heterozygous dele-
tions, bringing the total to 1.3% (8/604) (Table 1). All
probands were of European ancestry. To determine the
frequency in population controls, we initially used a
qPCR assay to screen a panel of North American Cauca-
sians and found the heterozygous deletion at a similar
frequency of ~1.6% (3/186). Subsequent analysis of
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nately European ancestry yielded heterozygous PTCHD3
deletion frequencies of ~0.67% (8/1,152) [17], 0.36% (4/
1,123) [18], and 0.97% (12/1,234) [19] (Table 1). Though
the deletions were at slightly elevated frequency in ASD,
we did not see a statistically significant association over
controls when considering all data (p = 0.13; Fisher’s
2-tailed exact test) (Table 1).
Although no obvious role for involvement in ASD was
found, we sought to determine the population frequency
and possible ancestral origin of the deletion by charac-
terizing the human genome diversity panel (HGDP-
CEPH), which is comprised of DNA samples from
worldwide populations [20]. We found heterozygous
PTCHD3 deletions in ~0.67% (7/1,043) individuals in
the HGDP-CEPH (Figure 1) including three of Palesti-
nian descent (from Israel Central), one of Druze descent
(from Israel Carmel), one of Balochi descent (from
Pakistan) and one of Northern Italian descent (from
Italy Bergamo). Thus the deletion appeared to be pre-
sent in those of Mediterranean/Middle East descent,
suggesting this population as the likely origin of the
ancestral CNV event. When we had sufficient family
histories on the autism families to assess geneology, they
were also found to have links to the Mediterranean/
Middle East regions.
Table 1 PTCHD3 deletions frequencies in Autism and control populations
Population Origin Method Total Number
unrelated
PTCHD3 del count Frequency (%) Reference
Autism Canada 500 K array 427 6 1.40 Marshall [16]
Canada qPCR 177 2 1.13 unpublished
Total 604 8 1.32
Control Canada 500 K array 1,152 8 0.69 Zogopolous [17]
Other qPCR 1,043 7 0.67 HGDP
N.America qPCR 186 3 1.61 Coriell, USA
Germany Affy6.0 1,123 4 0.36 Krawczak [18]
Canada Affy6.0 1,234 12 0.97 Stewart [19]
Total 4,552 31 0.68
p-value for cases versus controls is not significant (Fisher’s extact two tail; P = 0.13). 8/604 and 31/3695 + 648 = 4343 excluding the African, East Asian, and
Oceania populations from the HDGP samples.
Legend
S. America
Europe
Central/South 
Middle East
Africa
East Asia
Oceania
Human Genome Diversity Panel (7/1043)
North American Caucasian Panel (3/186)
(0/108)
(1/156)
(5/176)
(0/123)
(1/208)
(0/236)
(0/36)
N. America
(3/186)
Figure 1 Geographical population distribution of PTCHD3 deletions.
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Using several PCR assays (Figure 2, Additional file 1) we
defined and sequenced the breakpoints of the deletion,
eventually determining it was 102,624 base pairs in size
(spanning Chr.10: 27,643,753-Chr.10:27,746,377; NCBI
B u i l d3 5 ) .T h eb r e a k p o i n tw a sf o u n dt ob ei d e n t i c a li n
the eight ASD probands and seven HGDP-CEPH indivi-
duals tested, suggesting a single ancestral event. The dis-
tal 10p12.1 breakpoint resides in a segmental duplication
while the proximal end does not. Interestingly this
PTCHD3 CNV region corresponds to a human-murine
break of synteny with portions of murine chromosome 2
(inverted), chromosome 11 (inverted) and chromosome
18 mapping to human 10p12.1 [24] (Additional file 3).
No Obvious Clinical Phenotype in PTCHD3 Nulls
Of the eight ASD probands with deletions, we were able
to determine maternal inheritance in four families
(SK0191, SK0136, SK0257, MM0303) and paternal
inheritance in two families (SK0145, MM0145). For two
of the families, we did not have parental DNA. In one
family, SK0191, all three offspring were found to carry
the deletion and the mother was found to be homozy-
gous for the deletion. We confirmed transmission by
running the entire family (mother, father, proband, two
affected siblings) on the Affymetrix 500 K array and
subsequent PCR validation and breakpoint determina-
tion (Figure 3). The mother with the homozygous dele-
tion has no apparent abnormal phenotype.
To further characterize PTCHD3, we sequenced exons
in the families harboring deletions (Additional file 4).
We found two novel sequence variants that, in combina-
tion with the deletions, result in a null genotype. The
father in family MM0145 has a deletion (CNV) on one
allele compounded with a single base pair deletion at
A1767. This single nucleotide deletion results in a fra-
meshift introducing a stop codon at ~46 bp downstream
of the deleted base suggesting no functional PTCHD3
copy in this individual. However, this nucleotide variant
only affects the larger PTCHD3 isoform as the sequence
h a r b o r i n gi ti se x c l u d e df r o mt h en o v e ls h o r t e ri s o f o r m
we identified (see below). Family members from both
10p12.1
tel cen
Mb
Chr10
27.6 27.8 27.7
Genes
UCSC SD
Affy 500K
CNV
PCR primers
Sequence 
Breakpoint
PTCHD3 | NM_0034842
27,642,000 27,644,000 27,643,000 27,646,000 27,647,000 27,648,000
...A T A A T C T G T A
...T A T T A G A C A T
chr10:27,643,753 bp
T C T T T G A A G A...
A G A A A C T T C T...
chr10:27,746,377 bp
telomeric seq
centromeric seq
Cytoband
10p12.1
tel cen
Mb
Chr10
27.6 27.8 27.7
Genes
UCSC SD
Affy 500K
CNV
PCR primers
Sequence 
Breakpoint
PTCHD3 | NM_0034842
27,642,000 27,644,000 27,643,000 27,646,000 27,647,000 27,648,000
...A T A A T C T G T A
...T A T T A G A C A T
chr10:27,643,753 bp
T C T T T G A A G A...
A G A A A C T T C T...
chr10:27,746,377 bp
telomeric seq
centromeric seq
Cytoband
Figure 2 Genomic characterization of the PTCHD3 deletion variant. The cytoband and genomic coordinates (NCBI Build 35) are expanded
from the chromosome 10 ideogram. The PTCHD3 gene (black), UCSC segmental duplications (grey bars), and Affymetrix 500 K SNP probes (black
lines) are also shown. The deletion is denoted by a rectangle with hatched bars showing the sequenced breakpoints. Expansion of the region
shows the location of primers (arrows) used for sequencing with the telomeric (red) and centromeric (blue) breakpoint sequences.
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file 4) have CNV deletions and single base pair inser-
tions at 923G. Again, this single nucleotide insertion,
which in this case affects both the long and short
PTCHD3 isoforms, results in a frameshift introducing a
stop codon at ~75 bp downstream of the inserted base.
Both fathers have no obvious clinical phenotype and
have fathered children despite the suggested role of
PTCHD3 in sperm motility [25], indicating PTCHD3 is
not essential for fertility.
PTCHD3 Expression Profile and Functional Analysis
Due to the lack of an obvious phenotype in PTCHD3
nulls, we sought to further characterize the gene and rule
out the possibility of PTCHD3 being a pseudogene. Using
primer set A (Additional file 2) PTCHD3 expression was
evaluated by PCR in cDNA panels of adult and fetal tis-
sues. Although mouse Ptchd3 expression is testis-specific
[25], the RT-PCR performed on a diverse panel of human
cDNAs showed widespread expression in adult tissues
(pancreas, placenta, salivary gland, skin, spleen, thymus,
thyroid, trachea, bone marrow, brain, colon, heart, kid-
ney, lung, lymph node, tongue, testis, ovary, spinal cord)
and foetal sources (brain, bladder, kidney, lung, spleen
a n ds t o m a c h )( d a t an o ts h o w n ) .W ed i dn o td e t e c t
expression of PTCHD3 in adult mammary gland, skeletal
muscle, stomach, adrenal gland, cerebellum, fibroblasts,
liver, uterus and foetal liver, skeletal muscle, thymus and
aorta (data not shown). Expression appeared to be high-
est in adult lymph node, testes and tongue. Using a probe
detecting both PTCHD3 isoforms, the PTCHD3 expres-
sion was further confirmed by northern blot on RNAs
from 8 human tissues (Figure 4A). Despite apparent null
genotypes in some individuals, PTCHD3 is expressed in
human tissues.
Using primer set B (Additional file 2), expression in
lymph nodes showed amplification of a long and a short
isoform of PTCHD3 r u n n i n go na na g a r o s eg e la t
~2.3 kb and ~1.6 kb, respectively (Additional file 5).
Both isoforms were cloned into and expressed from a
pcDNA3 myc vector for further functional characteriza-
tion. Plasmids containing either short (1,602 bp from,
and including, start to stop codons) or long (2,304 bp
from, and including, start to stop codons) PTCHD3 iso-
forms were transfected into COS-7 cell line resulting in
the expression of a ~80 or ~115 kDa proteins, respec-
tively, as determined by Western blotting (Figure 4C).
Immunocytochemistry analysis using anti-Myc antibo-
dies demonstrated co-localization of both of the
PTCHD3 isoforms with calnexin to the endoplasmic
reticulum (Pearson correlation coefficient 0.85) (Figure
4D). The sequence of the newly characterized PTCHD3
isoform has been submitted to the GenBank (Genbank
accession number: JF332167).
Two Ptchd3 isoforms have been detected in mouse,
Ptchd3a (AK017136) (coding for 410 amino acids) and
Ptchd3b (AB235902) (coding for 906 amino acids), of
which the first encoded 409 amino acids are identical
[25]. In mice, Ptchd3 expression is developmentally
regulated and detected exclusively in testes [25]. Human
PTCHD3 shares ~63% amino acids identity with its
mouse orthologue and it has been shown that in both
species PTCHD3 is expressed and localized to the mid-
piece of sperm, suggesting possible involvement of
PTCHD3 in sperm motility and hence fertility [25].
However, we report healthy offspring fathered from
males in which both germline PTCHD3 alleles are
apparently inactive. It is possible that PTCHD3 can
improve fecundity, but its absence may not always be
accompanied by infertility.
The hedgehog (Hh) signaling pathway (including Hh
protein and its receptor Ptc) has important roles in
embryonal patterning and development in both verte-
brates and invertebrates [26]. PTCHD3 has Ptc and
Sterol Sensing (SSD) domains suggesting a possible role
for PTCHD3 in hedgehog signaling. Although, we can-
not exclude the possibility of PTCHD3 having an impor-
tant function in humans, our observation indicate that
the absence of PTCHD3 has no overt effect on normal
development. Nonetheless, whether there are some
~70 kb
1
0
p
1
2
.
1
cytoband SNP intensity heatmap
-/- +/+
-/+ -/+ -/+
log2
Figure 3 Segregation of a homozygous PTCHD3 deletion. The ‘-’
denotes the deleted allele and ‘+’ the non-deleted wild type allele.
Females are denoted by circles and males with squares. Individuals
with a diagnosis of ASD are black with the proband denoted by an
arrow. The heatmap profiles below show individual probe intensities
covering the deleted region (top, telomeric end) with white, pink,
and red signifying copy numbers of 0, 1, and 2, respectively. The
blue line shows the smoothed log2 ratio for the mother.
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1       2       3      4      5
A) B)
C)
Colon
Small intestine
Ovary
Testis
Prostate
Spleen
Thymus
5’ 3’
PTCHD3 short PTCHD3 short PTCHD3 short
PTCHD3 long PTCHD3 long PTCHD3 long
ER marker myc colocalized
ER marker myc colocalized
D)
Blood lymph
1       2       3      4      5
A) B)
C)
Colon
Small intestine
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PTCHD3 short PTCHD3 short PTCHD3 short
PTCHD3 long PTCHD3 long PTCHD3 long
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D)
Figure 4 Expression and localization of PTCHD3 isoforms. A: A multiple tissue northern blot demonstrating the expression profile of PTCHD3
isoforms in different tissues. B: A schematic demonstration of two predominant isoforms of PTCHD3 showing truncation of the last exon of
previously documented PTCHD3 isoform (coding sequence: 2,304 bps) in the newly identified isoform (coding sequence: 1,602 bps). C: Cloning
and expression of PTCHD3 isoforms tagged with a Myc epitope in COS-7 cells resulted in detection (by western blot) of two proteins of ~115
KDa (lanes 1 and 2) and ~80 KDa (lanes 3 and 4); lane 5: run with the lysates prepared from untransfected cells. D: Both PTCHD3 isoforms are
localised to the endoplasmic reticulum (ER). Immunostaining of COS-7 cells transfected with constructs expressing Myc-tagged short or longer
isoforms of PTCHD3 using antibodies detecting calnexin (red) as an ER marker and Myc epitope (green) demonstrated co-localization of PTCHD3
isoforms with calnexin to the ER (Pearson coefficient 0.85).
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whether this molecule might have beneficial effects
under certain conditions remains to be determined. It is
noteworthy that different individuals with the same het-
erozygous deletions, e.g. 16p11.2 microdeletions [27-30],
can present a spectrum of phenotypes. In another exam-
ple, a sib pair was recently reported to both have large
homozygous chromosomal deletion (812-902 kb) at
chromosome 12q21.1, but while one sib demonstrated
dysmorphic features and developmental delay, the other
child was unaffected [31]. The variable penetrance may
arise due to unshared genes between the sibs, highlight-
ing the need to interpret CNV data in a genome-wide
context [7,32].
Conclusion
We identified a novel 102.6 kb CNV ancestral deletion on
chromosome 10p12.1 that is predominantly present in
European/Middle Eastern populations and encompasses
the PTCHD3 gene. A novel shorter ~1.6 kb isoform of
PTCHD3 (Genbank accession number: JF332167) was
also characterized. Expression studies revealed that both
the long and short PTCHD3 isoforms co-localize with
calnexin to the endoplasmic reticulum. We demonstrate
that a PTCHD3 null state can exist in humans through
homozygous deletions, or combinations of deletions and
single nucleotide mutations, with no overt abnormal
phenotype being associated. Our data helps further define
the essential human gene set.
Additional material
Additional file 1: A Table listing the primers used for breakpoint
mapping.
Additional file 2: A table listing primers used for RT-PCR, cloning
and northern blot.
Additional file 3: A figure depicting murine break of synteny at
ptchd3 region versus human.
Additional file 4: Pedigrees demonstrating compounded PTCHD3
mutations complexion in families with individuals affected with
ASD.
Additional file 5: A figure depicting PTCHD3 expression in human
lymph node (L.N.) detected by RT-PCR.
List of Abbreviations
CNV: Copy Number Variation; ASD: Autism Spectrum Disorders; MTN:
Multiple Tissue Northern Blot; Hh: Hedghog; HGDP: Human Genome
Diversity Panel; BSA: Bovine Serum Albumin.
Acknowledgements
This work is supported by The Centre for Applied Genomics, Genome
Canada/Ontario Genomics Institute, the Canadian Institutes of Health
Research (CIHR), the McLaughlin Centre, the Canadian Institute of Advanced
Research, the Hospital for Sick Children (SickKids) Foundation, and the
Autism Research Training Program. MMGHS is supported by a fellowship
from Autism Speaks, USA. S.W.S holds the GlaxoSmithKline-CIHR Pathfinder
Chair in Genetics and Genomics at the University of Toronto and the
Hospital for Sick Children (Canada).
Author details
1The Centre for Applied Genomics and Program in Genetics and Genome
Biology, The Hospital for Sick Children, Toronto, Ontario M5G 1L7, Canada.
2Department of Pathobiology, School of Veterinary Medicine, Shiraz
University, Shiraz, Iran.
3McLaughlin Centre and Department of Molecular
Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
Authors’ contributions
MMGHS, BK, KKML, RM, ACL, and CRM performed laboratory and
computational analyses. MMGHS, RM, CRM and SWS designed the study,
interpreted the data and wrote the manuscript. All authors read and
approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 September 2010 Accepted: 26 March 2011
Published: 26 March 2011
References
1. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al:
Detection of large-scale variation in the human genome. Nat Genet 2004,
36:949-951.
2. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al: Large-
scale copy number polymorphism in the human genome. Science 2004,
305:525-528.
3. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al: Global
variation in copy number in the human genome. Nature 2006,
444:444-454.
4. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, et al: Origins
and functional impact of copy number variation in the human genome.
Nature 2010, 464:704-712.
5. Feuk L, Carson AR, Scherer SW: Structural variation in the human
genome. Nat Rev Genet 2006, 7:85-97.
6. Beckmann JS, Estivill X, Antonarakis SE: Copy number variants and genetic
traits: closer to the resolution of phenotypic to genotypic variability. Nat
Rev Genet 2007, 8:639-646.
7. Lee C, Scherer SW: The clinical context of copy number variation in the
human genome. Expert Rev Mol Med 2010, 12:e8.
8. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, et al: The diploid
genome sequence of an individual human. PLoS Biol 2007, 5:e254.
9. Pang AW, Macdonald JR, Pinto D, Wei J, Rafiq MA, Conrad DF, et al:
Towards a comprehensive structural variation map of an individual
human genome. Genome Biol 2010, 11:R52.
10. McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC, et al:
Common deletion polymorphisms in the human genome. Nat Genet
2006, 38:86-92.
11. Olson MV: When less is more: gene loss as an engine of evolutionary
change. Am J Hum Genet 1999, 64:18-23.
12. Wang X, Grus WE, Zhang J: Gene losses during human origins. PLoS Biol
2006, 4:e52.
13. Tournamille C, Colin Y, Cartron JP, Le Van KC: Disruption of a GATA motif
in the Duffy gene promoter abolishes erythroid gene expression in
Duffy-negative individuals. Nat Genet 1995, 10:224-228.
14. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al:
Resistance to HIV-1 infection in caucasian individuals bearing mutant
alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
15. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J,
Combadiere C, et al: Inherited resistance to HIV-1 conferred by an
inactivating mutation in CC chemokine receptor 5: studies in
populations with contrasting clinical phenotypes, defined racial
background, and quantified risk. Mol Med 1997, 3:23-36.
16. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, et al: Structural
variation of chromosomes in autism spectrum disorder. Am J Hum Genet
2008, 82:477-488.
17. Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A, et al: Germ-
line DNA copy number variation frequencies in a large North American
population. Hum Genet 2007, 122:345-353.
Ghahramani Seno et al. BMC Medical Genetics 2011, 12:45
http://www.biomedcentral.com/1471-2350/12/45
Page 8 of 918. Krawczak M, Nikolaus S, von Eberstein H, Croucher PJ, El Mokhtari NE,
Schreiber S: PopGen: population-based recruitment of patients and
controls for the analysis of complex genotype-phenotype relationships.
Community Genet 2006, 9:55-61.
19. Stewart AF, Dandona S, Chen L, Assogba O, Belanger M, Ewart G, et al:
Kinesin family member 6 variant Trp719Arg does not associate with
angiographically defined coronary artery disease in the Ottawa Heart
Genomics Study. J Am Coll Cardiol 2009, 53:1471-1472.
20. Cann HM, de Toma C, Cazes L, Legrand MF, Morel V, Piouffre L, et al: A
human genome diversity cell line panel. Science 2002, 296:261-262.
21. Noor A, Whibley A, Marshall CR, Gianakopoulos PJ, Piton A, Carson AR, et al:
Disruption at the PTCHD1 Locus on Xp22.11 in Autism Spectrum
Disorder and Intellectual Disability. Sci Transl Med 2010, 2:49ra68.
22. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al:
Functional impact of global rare copy number variation in autism
spectrum disorders. Nature 2010, 466:368-372.
23. Whibley AC, Plagnol V, Tarpey PS, Abidi F, Fullston T, Choma MK, et al:
Fine-scale survey of X chromosome copy number variants and indels
underlying intellectual disability. Am J Hum Genet 2010, 87:173-188.
24. Armengol L, Pujana MA, Cheung J, Scherer SW, Estivill X: Enrichment of
segmental duplications in regions of breaks of synteny between the
human and mouse genomes suggest their involvement in evolutionary
rearrangements. Hum Mol Genet 2003, 12:2201-2208.
25. Fan J, Akabane H, Zheng X, Zhou X, Zhang L, Liu Q, et al: Male germ cell-
specific expression of a novel Patched-domain containing gene Ptchd3.
Biochem Biophys Res Commun 2007, 363:757-761.
26. Alcedo J, Noll M: Hedgehog and its patched-smoothened receptor
complex: a novel signalling mechanism at the cell surface. Biol Chem
1997, 378:583-590.
27. Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, et al:
Large, rare chromosomal deletions associated with severe early-onset
obesity. Nature 2010, 463:666-670.
28. Fernandez BA, Roberts W, Chung B, Weksberg R, Meyn S, Szatmari P, et al:
Phenotypic spectrum associated with de novo and inherited deletions
and duplications at 16p11.2 in individuals ascertained for diagnosis of
autism spectrum disorder. J Med Genet 2010, 47:195-203.
29. Sampson MG, Coughlin CR, Kaplan P, Conlin LK, Meyers KE, Zackai EH, et al:
Evidence for a recurrent microdeletion at chromosome 16p11.2
associated with congenital anomalies of the kidney and urinary tract
(CAKUT) and Hirschsprung disease. Am J Med Genet A 2010.
30. Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D, Andersson J,
et al: A new highly penetrant form of obesity due to deletions on
chromosome 16p11.2. Nature 2010, 463:671-675.
31. Curry CJ, Mao R, Aston E, Mongia SK, Treisman T, Procter M, et al:
Homozygous deletions of a copy number change detected by array
CGH: a new cause for mental retardation? Am J Med Genet A 2008,
146A:1903-1910.
32. Ali-Khan SE, Daar AS, Shuman C, Ray PN, Scherer SW: Whole genome
scanning: resolving clinical diagnosis and management amidst complex
data. Pediatr Res 2009, 66:357-363.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/45/prepub
doi:10.1186/1471-2350-12-45
Cite this article as: Ghahramani Seno et al.: Human PTCHD3 nulls: rare
copy number and sequence variants suggest a non-essential gene. BMC
Medical Genetics 2011 12:45. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ghahramani Seno et al. BMC Medical Genetics 2011, 12:45
http://www.biomedcentral.com/1471-2350/12/45
Page 9 of 9